75N94020D00003 - PK/PD, metabolic, and preclinical studies - SRI international - can 8030701 research and development within preclinical studies encompassing but not limited to PK/PD studies and…
Ended Awarded Last action
- Contract number
- 75N94023F00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,084,983
Award facts
- Contract value 100% obligated
- $2,084,983.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $2,084,983 |
About this award
The National Institute of Child Health and Human Development (NICHD) awarded a delivery order valued at $2.08M to SRI International for preclinical research and development activities focused on pharmacokinetics/pharmacodynamics (PK/PD) studies and metabolic profiling of contraceptive agents. This non-severable contract, issued on April 13, 2023, with an ultimate completion date of December 12, 2025, will be performed at SRI International's Menlo Park, California facility under a cost-plus-fixed-fee arrangement with no small business set-aside. The work encompasses comprehensive preclinical studies to characterize the absorption, distribution, metabolism, and elimination properties of investigational contraceptive compounds, supporting regulatory submissions and clinical development pathways.
SRI International has engaged two subcontractors to execute specialized components of this research. The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, subcontracted in August 2024, will perform bioanalytical testing to quantify dimethandrolone undecanoate (DMAU) and its active metabolite dimethandrolone (DMA) in serum samples collected from Sprague Dawley female rats. Washington State University, subcontracted in June 2023, will conduct metabolite identification and mechanism of elimination studies for 11β-MNT, another investigational contraceptive candidate. These combined efforts will generate critical safety and efficacy data to support the development of novel hormonal contraceptive options.
Description
75N94020D00003 - PK/PD, metabolic, and preclinical studies - SRI international - can 8030701 research and development within preclinical studies encompassing but not limited to PK/PD studies and metabolic profiling of contraceptive agents.
Quick answers
Who was awarded contract 75N94023F00001?
75N94023F00001 was awarded to Sri International by National Institute of Child Health and Human Development (National Institutes of Health) on April 13, 2023.
How much is contract 75N94023F00001 worth?
The government has obligated $2,084,983 on 75N94023F00001.
Is contract 75N94023F00001 an order under another contract?
Yes. 75N94023F00001 is a delivery order under 75N94020D00003, an indefinite delivery contract.
Was contract 75N94023F00001 competed?
The extent of competition for 75N94023F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award